1 April 1991 in Journal of Endocrinological Investigation
24 July 2024 in JCEM Case Reports
Type 1 diabetes mellitus (T1DM) and congenital adrenal hyperplasia (CAH) are 2 complex endocrine disorders with neighboring genetic loci. We present a case of T1DM onset in a 6-year-old child, already affected by 21-hydroxylase deficiency (salt-wasting CAH) diagnosed at 18 days of age, who was referred to our clinic because of typical symptoms of diabetes despite nondiagnostic fasting blood glucose values. Further analysis revealed elevated glycated hemoglobin (HbA1c), low C-peptide, and specific autoantibodies suggesting the diagnosis of T1DM. Although he only started with rapid-acting insulin analogue before meals, he presented spontaneous episodes of hypoglycemia just before the morning hydrocortisone dose, due to an underdosed glucocorticoid intake. Based on continuous glycemic monitoring (CGM), his morning dose was increased and given earlier; then we decided to apply an advanced hybrid closed-loop insulin pump to maintain glycemic time in range above 70%. Fasting glucose in CAH patients can be lower due to underdosed glucocorticoid replacement therapy. HbA1c and CGM can help recognize T1DM onset and evaluate the correct dosage of corticosteroid therapy in CAH patients. New studies are needed to understand the therapeutic approach for a more specific treatment in case of coexistence of these diseases.
14 September 2026 in Diabetes, Obesity and Metabolism
Introduction: Use of automated insulin delivery (AID) systems during physical activity and exercise (PA) is safe and associated with improved glucose outcomes when compared with insulin pump therapy in manual mode and insulin pen therapy, provided that appropriate adjustments to insulin doses and carbohydrate intake are ensured. Aim: This expert guidance aimed to support healthcare professionals in educating Control‐IQ (Tandem Diabetes Care) users on PA management. Methods: Based on international recommendations, including the recent EASD/ISPAD position statement on AID and exercise, as well as on the authors' clinical experience, we developed practical flowcharts and accompanying information that provide step‐by‐step guidance for PA management in children, adolescents and adults with type 1 diabetes using the Control‐IQ technology. Results: Operational instructions were outlined across four different scenarios, with additional advice on insulin pump suspension where required. In each of the scenarios, we highlighted the possibility of activating a Personal Profile with more or less insulin, a unique feature of the Control‐IQ algorithm that can be used simultaneously with the Exercise Activity feature. Conclusion: We believe that this expert guidance, with its practical flowcharts, can help simplify decision‐making for Control‐IQ users.